Logo image of IMAB

I-MAB-SPONSORED ADR (IMAB) Stock Fundamental Analysis

NASDAQ:IMAB - Nasdaq - US44975P1030 - ADR - Currency: USD

0.99  -0.06 (-5.71%)

Fundamental Rating

3

Taking everything into account, IMAB scores 3 out of 10 in our fundamental rating. IMAB was compared to 562 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMAB as it has an excellent financial health rating, but there are worries on the profitability. IMAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMAB had negative earnings in the past year.
IMAB had a negative operating cash flow in the past year.
IMAB had negative earnings in 4 of the past 5 years.
In the past 5 years IMAB reported 4 times negative operating cash flow.
IMAB Yearly Net Income VS EBIT VS OCF VS FCFIMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

With an excellent Return On Assets value of -10.33%, IMAB belongs to the best of the industry, outperforming 84.70% of the companies in the same industry.
With an excellent Return On Equity value of -10.95%, IMAB belongs to the best of the industry, outperforming 88.26% of the companies in the same industry.
Industry RankSector Rank
ROA -10.33%
ROE -10.95%
ROIC N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
IMAB Yearly ROA, ROE, ROICIMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

IMAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAB Yearly Profit, Operating, Gross MarginsIMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

7

2. Health

2.1 Basic Checks

IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMAB has more shares outstanding
IMAB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMAB Yearly Shares OutstandingIMAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IMAB Yearly Total Debt VS Total AssetsIMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of -4.29, we must say that IMAB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.29, IMAB perfoms like the industry average, outperforming 44.31% of the companies in the same industry.
There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.29
ROIC/WACCN/A
WACC9.84%
IMAB Yearly LT Debt VS Equity VS FCFIMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

IMAB has a Current Ratio of 20.95. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IMAB (20.95) is better than 94.66% of its industry peers.
A Quick Ratio of 20.95 indicates that IMAB has no problem at all paying its short term obligations.
The Quick ratio of IMAB (20.95) is better than 94.66% of its industry peers.
Industry RankSector Rank
Current Ratio 20.95
Quick Ratio 20.95
IMAB Yearly Current Assets VS Current LiabilitesIMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

IMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.81%, which is quite impressive.
Looking at the last year, IMAB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.36% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.7%
EPS Next 2Y32.74%
EPS Next 3Y19.57%
EPS Next 5Y21.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMAB Yearly Revenue VS EstimatesIMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 0 500M 1B 1.5B
IMAB Yearly EPS VS EstimatesIMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMAB. In the last year negative earnings were reported.
Also next year IMAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAB Price Earnings VS Forward Price EarningsIMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMAB Per share dataIMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

IMAB's earnings are expected to grow with 19.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.74%
EPS Next 3Y19.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

I-MAB-SPONSORED ADR

NASDAQ:IMAB (5/23/2025, 8:25:08 PM)

0.99

-0.06 (-5.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-26 2025-08-26
Inst Owners15.29%
Inst Owner Change-22.65%
Ins Owners0.67%
Ins Owner ChangeN/A
Market Cap80.07M
Analysts82.22
Price Target5.61 (466.67%)
Short Float %1.06%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22%
Min EPS beat(2)-38.4%
Max EPS beat(2)-5.6%
EPS beat(4)2
Avg EPS beat(4)6.9%
Min EPS beat(4)-38.4%
Max EPS beat(4)65.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10%
PT rev (3m)-2.94%
EPS NQ rev (1m)40.91%
EPS NQ rev (3m)40.91%
EPS NY rev (1m)42.31%
EPS NY rev (3m)68.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.33%
ROE -10.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.95
Quick Ratio 20.95
Altman-Z -4.29
F-Score4
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)76.01%
Cap/Depr(5y)97.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
EPS Next Y84.7%
EPS Next 2Y32.74%
EPS Next 3Y19.57%
EPS Next 5Y21.36%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3Y34.96%
EBIT Next 5Y74.68%
FCF growth 1Y56.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.04%
OCF growth 3YN/A
OCF growth 5YN/A